<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">In view of good tolerability of HCQ and low cost, it could be offered as an off-label treatment to the patients with moderate to severe COVID-19 infection. These issues have been discussed in detail in another article in this special issue [
 <xref rid="bib15" ref-type="bibr">15</xref>].
</p>
